Pyridine → N-(6-ethyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)imidazolidine-1-carboxamide

HRID 2279009Notes

Reaction equation

HRID 2279009 reaction equation
[O:1]1[CH2:6][CH2:5][CH:4]([N:7]2[CH2:11][CH2:10][NH:9][C:8]2=[O:12])[CH2:3][CH2:2]1.N1C=CC=CC=1.[C:19](Cl)(Cl)=[O:20].[CH2:23]([C:25]1[N:30]=[C:29]([NH2:31])[CH:28]=[CH:27][C:26]=1[O:32][C:33]1[CH:38]=[CH:37][N:36]=[C:35]([C:39]2[CH:40]=[N:41][C:42]([CH3:45])=[CH:43][CH:44]=2)[CH:34]=1)[CH3:24]>C(Cl)Cl>[CH2:23]([C:25]1[N:30]=[C:29]([NH:31][C:19]([N:9]2[CH2:10][CH2:11][N:7]([CH:4]3[CH2:3][CH2:2][O:1][CH2:6][CH2:5]3)[C:8]2=[O:12])=[O:20])[CH:28]=[CH:27][C:26]=1[O:32][C:33]1[CH:38]=[CH:37][N:36]=[C:35]([C:39]2[CH:40]=[N:41][C:42]([CH3:45])=[CH:43][CH:44]=2)[CH:34]=1)[CH3:24]

Participants

6

Reactant 4

HCID 1049Pyridine2×HCID 6371PhosgeneHCID 904259751-(Oxan-4-yl)imidazolidin-2-oneHCID 904265476-Ethyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-amine

Product 1

HCID 86269026N-(6-ethyl-5-((6'-methyl-[2,3'-bipyridin]-4-yl)oxy)pyridin-2-yl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)imidazolidine-1-carboxamideYield 7.2%

Reagents, catalysts & solvents 1

HCID 6344DichloromethaneSolvent2×

Procedure

A 0° C. solution of Example B1 (0.19 g, 1.116 mmol) and pyridine (0.26 mL, 3.21 mmol) in DCM (5 mL) was treated drop-wise with phosgene (20% in toluene, 1.4 mL, 2.65 mmol) and warmed to RT over 0.5 h. The mixture was treated slowly with a solution of 6-ethyl-5-((6′-methyl-[2,3′-bipyridin]-4-yl)oxy)pyridin-2-amine (0.16 g, 0.522 mmol) and pyridine (0.16 mL, 1.978 mmol) in DCM (5 mL) and stirred at RT overnight. The mixture was treated with satd. NaHCO3, extracted with EtOAc (4×) and the combined organics were dried over MgSO4, concentrated to dryness, purified via silica gel chromatography (MeOH/DCM), then re-purified via reverse-phase chromatography (MeCN/H2O with 0.1% TFA). The combined fractions were treated with satd. NaHCO3, extracted with DCM (5×) and the combined organics were dried over MgSO4 and concentrated to dryness to afford N-(6-ethyl-5-((6′-methyl-[2,3′-bipyridin]-4-yl)oxy)pyridin-2-yl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)imidazolidine-1-carboxamide (19 mg, 7%). 1H NMR (400 MHz, DMSO-d6): δ 10.93 (s, 1 H), 9.09 (d, J=2.4 Hz, 1 H), 8.52 (d, J=5.7 Hz, 1 H), 8.28 (dd, J=8.1, 2.4 Hz, 1 H), 7.90 (d, J=8.8 Hz, 1 H), 7.64 (d, J=8.8 Hz, 1 H), 7.59 (d, J=2.4 Hz, 1 H), 7.33 (d, J=8.2 Hz, 1H), 6.77 (dd, J=5.7, 2.4 Hz, 1 H), 3.94-3.84 (m, 3 H), 3.83-3.79 (m, 2 H), 3.46 (t, J=8.2 Hz, 2 H), 3.38 (t, J=11.6 Hz, 2 H), 2.58 (q, J=7.5 Hz, 2 H), 2.50 (s, 3 H), 1.72 (dd, J=12.3, 4.5 Hz, 2 H), 1.62 (s, 2 H), 1.12 (t, J=7.5 Hz, 3H); MS (ESI) m/z: 503.3 (M+H+).

Workup

  1. additionThe mixture was treated with satd
  2. extractionNaHCO3, extracted with EtOAc (4×)
  3. dry with materialthe combined organics were dried over MgSO4
  4. concentrationconcentrated to dryness
  5. custompurified via silica gel chromatography (MeOH/DCM)
  6. customre-purified via reverse-phase chromatography (MeCN/H2O with 0.1% TFA)
  7. additionThe combined fractions were treated with satd
  8. extractionNaHCO3, extracted with DCM (5×)
  9. dry with materialthe combined organics were dried over MgSO4
  10. concentrationconcentrated to dryness

Sources & evidence

ORD record
ord-74742d3d81a3463b9c3438d2de77962d
Source dataset
uspto-grants-2015_09
Patent number
US09133183B2

Reaction notes

Loading…